Abstract:RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression in pancreatic cancer and their relationship with overall survival (OS) time, and evaluated their significance as therapeutic targets of tyrosine kinase inhibitors in pancreatic cancer. We enrolled 227 patients with pancreatic cancer in the study. RON and MET expression was analyzed by immunohistochemical staining. Four human pancreatic cancer cell lines expressing variable levels of RON or MET and four MET superfamily inhibitors (BMS777607, PHA665752, INCB28060, Tivantinib) were used. The effect of the four tyrosine kinase inhibitors on cell viability, migration, and apoptosis were determined using cell viability, scratch wound healing, and Caspase-Glo 3/7 assays. Cellular signaling was analyzed by immunoprecipitation and western blotting. The therapeutic efficacy of the tyrosine kinase inhibitors was determined with mouse xenograft pancreatic cancer models in vivo. There was wide aberrant RON and MET expression in the cancer tissues. In 227 pancreatic cancer samples, 33% had RON overexpression, 41% had MET overexpression, and 15.4% had RON and MET co-overexpression. RON and MET expression were highly correlated. RON and MET expression levels were significantly related to OS. Patients with RON and MET co-overexpression had poorer OS. BMS777607 and PHA665752 inhibited pancreatic cancer cell viability and migration, and promoted apoptosis by inhibiting RON and MET phosphorylation and further inhibiting the downstream signaling pathways in vitro. They also inhibited tumor growth and further inhibited phosphorylated (phosphor)-RON and phospho-MET expression in the mouse xenograft models in vivo effectively. INCB28060, which inhibits the MET signaling pathway alone, was not effective. RON and MET can be important indicators of prognosis in pancreatic cancer. Tyrosine kinase inhibitors targeting RON and MET in pancreatic cancer are a novel and potential approach for pancreatic cancer therapy.

ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer

High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer

High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS

Identification And Characterization Of Ano9 In Stage Ii And Iii Colorectal Carcinoma

Involvement of TMEM16A/ANO1 upregulation in the oncogenesis of colorectal cancer.

Downregulation of ANO1 activity in PC‐9 cells modulated by a new novel candidate TMEMinh001

Involvement of TMEM16A/ANO1 Upregulation in the Oncogenesis of Colorectal Cancer

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

TMEM16A as a Potential Biomarker in the Diagnosis and Prognosis of Lung Cancer

Inhibition of Ca2+-activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma

ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis

Role of ANO1 in Tumors and Tumor Immunity

Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery

ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts

ANO1 Protein As a Potential Biomarker for Esophageal Cancer Prognosis and Precancerous Lesion Development Prediction.

TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis

Exploring the Diversified Roles of Anoctamin Family in Pan-Cancer

Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer

ANO9 regulates PD‐L2 expression and binding ability to PD‐1 in gastric cancer

Inhibition of ANO1/TMEM16A Induces Apoptosis in Human Prostate Carcinoma Cells by Activating TNF-α Signaling.

Overexpression of ankyrin1 promotes pancreatic cancer cell growth.